Update from FARA and Everest Clinical Research
Everest Clinical Research and the Friedreich’s Ataxia Research Alliance (FARA) today announced a partnership focused on making patient-centered Friedreich’s ataxia (FA) data more accessible and actionable to help accelerate the development of treatments for FA.
As part of the collaboration, Everest Clinical Research will serve as a biostatistics partner for the FA Global Clinical Consortium (FA GCC). The FA GCC has built one of the most comprehensive collections of patient data in Friedreich’s ataxia, including longitudinal, clinical, biomarker, and outcomes data collected from patients worldwide. Through this initiative, Everest will provide independent biostatistical expertise to FA GCC members—including biopharma companies and academic researchers—helping translate data into meaningful insights that inform clinical trial design and therapeutic development.
Learn more about the partnership in the full press release.
